论文信息 - Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain - 字舞流文

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

A. Jiménez-Velasco | J. Martínez-López | J. Hernández-Boluda | M. Gomez-Casares | M. Ferrario | Irmina Gozalbo | J. Gostkorzewicz | R. Subirá | J. Martínez‐López | J. Hernández‐Boluda | M. Gómez-Casares